Zeziphi ezinye iindlela ezinokuchaphazeleka kwiiStatins?

Umxholo

• Malunga ne-PCSK9 Inhibitors
• Unyango olutsha lwe-Inhibitor
• Uphando lwamva nje
• Iindleko
• Ixesha elizayo le-PCSK9 Inhibitors

Ngokuka, malunga nabantu abangama-610,000 babulawa sisifo sentliziyo e-United States minyaka le. Isifo sentliziyo sisona sizathu siphambili sokufa kwamadoda nabasetyhini.

Kuba i-cholesterol ephezulu yingxaki exhaphakileyo, amayeza amatsha ebekhona ekuncedeni ukuyilawula. I-PCSK9 inhibitors yeyona ndlela intsha yamayeza emfazweni ngokuchasene nesifo sentliziyo.

Ezi ziyobisi zithoba i-cholesterol zisebenza ukwandisa isibindi sakho ekususeni i-cholesterol "embi" ye-LDL egazini lakho kwaye ke ukunciphisa umngcipheko wokuhlaselwa sisifo sentliziyo okanye ukubetha.

Qhubeka ufunda ukuze ufumane i-PCSK9 inhibitors, kunye nendlela abanokukunceda ngayo.

Malunga ne-PCSK9 Inhibitors

I-PCSK9 inhibitors inokusetyenziswa kunye okanye ngaphandle kokongezwa kwe-statin, nangona kunjalo zinokunceda ukunciphisa i-cholesterol ye-LDL ngama-75 epesenti xa isetyenziswa ngokudibene nesiyobisi se-statin.

Oku kunokuba luncedo ngakumbi kwabo bangakwaziyo ukunyamezela iintlungu zemisipha kunye nezinye iziphumo ebezingalindelekanga ze-statins okanye abo bangakwaziyo ukulawula i-cholesterol yabo ngokusebenzisa ii-statins zodwa.

Idosi yokuqala ecetyiswayo yi-75 mg injected kanye qho kwiiveki ezimbini. Le dosi inokunyuswa iye kwi-150 mg rhoqo kwiiveki ezimbini ukuba ugqirha wakho uziva ukuba amanqanaba akho e-LDL akaphenduli ngokwaneleyo kwidosi encinci.

Ngelixa iziphumo zophando kunye nokuvavanywa kwezi ziyobisi ngenaliti zisesezintsha, zibonisa ithemba elikhulu.

Unyango olutsha lwe-Inhibitor

Ixabiso elivunyiweyo kutshanje (alirocumab) kunye ne-Repatha (evolocumab), unyango lokuqala lwe-cholesterol-yokwehlisa inaliti kwiklasi entsha ye-PCSK9 inhibitors. Ziyilelwe ukuba zisetyenziswe ngokudibeneyo nonyango lwe-statin kunye notshintsho kwindlela otya ngayo.

Ixabiso kunye neRedatha yeyabantu abadala abane-heterozygous Family hypercholesterolemia (HeFH), imeko ezuzwe njengelifa ebangela amanqanaba aphezulu e-LDL cholesterol egazini, kunye nabo banesifo sentliziyo.

La machiza ngamachiza omzimba ajolise kwiprothini emzimbeni obizwa ngokuba yi-PCSK9. Ngokuthintela ukusebenza kwe-PCSK9 yokusebenza, ezi ntsholongwane ziyakwazi ukulahla i-cholesterol ye-LDL egazini kunye nokunciphisa amanqanaba e-cholesterol e-LDL ngokubanzi.

Uphando lwamva nje

Izilingo kunye nophando lubonakalisile iziphumo ezilungileyo kuzo zombini eziXabisekileyo kunye neRedatha. Kuvavanyo lwakutsha nje kwiRedatha, abathathi-nxaxheba abane-HeFH kunye nabanye abanomngcipheko ophezulu wokuhlaselwa sisifo sentliziyo okanye ukubetha ngesibetho behlisa i-cholesterol yabo ye-LDL ngomndilili.

Iziphumo ebezingalindelekanga ezixeliweyo zeRedatha zezi:

• usulelo lwephepha lokuphefumla
• nasopharyngitis
• umqolo obuhlungu
• umkhuhlane
• ukutyumka, ukubomvu, okanye iintlungu kwindawo yenaliti

Ukuphendula ngokuthe ngqo, kubandakanya urticaria kunye nokukhawuleza, nako kwaqwalaselwa.

Olunye ulingo kusetyenziswa ukuxabiseka kukwabonakalise iziphumo ezilungileyo. Aba bathathi-nxaxheba, ababesele besebenzisa unyango lwe-statin kwaye babe ne-HeFH okanye ukwanda komngcipheko wokubetha okanye ukuhlaselwa yintliziyo, babone ukwehla kwe-cholesterol ye-LDL.

Ukusetyenziswa okuxabisekileyo kwakufana neRedatha, kubandakanya:

• iintlungu nokugruzuka kwindawo yenaliti
• Iimpawu ezinjengomkhuhlane
• nasopharyngitis
• negazi lakho, ezifana hypersensitivity vasculitis

Iindleko

Njengakwimeko yenkqubela phambili yamayeza, la machiza amatsha enaliti aya kuza nexabiso eliphezulu. Ngelixa iindleko zezigulana ziya kuxhomekeka kwisicwangciso seinshurensi, iindleko zexabiso eliphezulu ziqala kwi- $ 14,600 ngonyaka.

Xa kuthelekiswa, igama lesiyobisi igama elithi statin lixabisa kuphela i-500 ukuya kwi-700 yeedola ngonyaka, kwaye loo manani ehla kakhulu xa kuthengwa ifom ye-generic statin.

Abahlalutyi balindele ukuba amachiza aqhubele phambili kwindawo yokuthengisa kakhulu ngexesha lokurekhoda kwaye angenise iibhiliyoni zeedola kwintengiso entsha.

Ixesha elizayo le-PCSK9 Inhibitors

Uvavanyo lusaqhuba malunga nokusebenza kwala machiza enaliti. Amanye amagosa ezempilo anexhala lokuba amachiza amatsha abangela ubungozi be-neurocognitive, ngenxa yokuba abanye abathathi-nxaxheba bexela ubunzima ngokudideka kunye nokungakwazi ukuthathela ingqalelo.

Uvavanyo olukhulu lweklinikhi luya kugqitywa ngo-2017.